Description

GLP-3 (RT) 20mg — retatrutide research peptide, Canada
Researched & reviewed by the SPO Quality Team · Last reviewed: 30 September 2026

This 20mg vial holds retatrutide, the Eli Lilly molecule coded LY3437943 and listed in this catalogue as GLP-3 (RT). One synthetic peptide chain carries agonist activity at three receptors — GIP, GLP-1 and glucagon — which is why the literature calls it a “triple agonist”[1]. The compound reached phase 2 in 2023 and phase 3 afterwards, but as of this review no regulator has approved it[2, 3]. What is sold here is lyophilized research-grade peptide for laboratory use, not the clinical product.

Full research overview, study table & references → GLP-3 (retatrutide) in Canada: research guide

Identity at a glance
Compound Retatrutide (INN); LY3437943; catalogue name “GLP-3 (RT)”
Structure 39-residue single-chain peptide with a C20 fatty-diacid side chain at Lys17 and Aib at positions 2 and 20; C-terminal amide (FDA GSRS)
Formula / MW C221H342N46O68 / 4731 g/mol (PubChem CID 171390338)
CAS 2381089-83-2
Receptors studied GIP, GLP-1 and glucagon receptors — one molecule, three targets[1]
Status Investigational (Eli Lilly); not approved anywhere[2]
Batch documentation
A batch-specific COA for this strength has not been posted yet — see the COA library (/coa/). The only retatrutide report in the library was run on a 10 mg vial lot; it does not describe this 20 mg vial and is deliberately not reproduced here. A 20 mg batch report will be embedded when one is issued.

What researchers have looked at
Phase 2, obesity (2023, 338 adults, 48 weeks): body weight fell dose-dependently relative to placebo across the arms tested; gastrointestinal adverse events were the most common, were dose-related and mostly mild to moderate, and heart rate rose dose-dependently, peaking at 24 weeks before declining[2].
Phase 2, type 2 diabetes (2023): a randomised, double-blind trial with placebo and active comparator in the USA examined glycaemic and weight endpoints[3]; a DXA substudy of 189 participants measured fat and lean mass changes, with fat-mass reductions that increased with dose[4].
Liver fat (2024): in a substudy of the obesity trial, participants with steatotic liver disease showed liver-fat reductions that tracked changes in body weight, abdominal fat and insulin-sensitivity measures[5].
Pooled analyses (2025–2026): a systematic review of three trials (1,082 screened, 691 randomised) confirmed gastrointestinal effects as the dominant adverse events[6]; a meta-analysis found lower systolic and diastolic blood pressure and lower total and LDL cholesterol on treatment[7].
Every item above describes a pharmaceutical-grade investigational drug given under medical supervision in a registered trial. The vial on this page has not been studied, and no effect is claimed for it.

Storage and handling
Keep the sealed vial frozen at −20 °C for long-term storage (the site’s stated stability is up to 24 months as dry powder); a cool, dry, dark shelf is acceptable for short periods; do not cycle it through repeated freeze–thaw.
The fatty-acid side chain makes retatrutide prone to self-association in solution, so dissolve only the quantity an experiment requires. Protocols for reconstitution and handling are the researcher’s responsibility and are not published on this site.
Also listed: GLP-3 (RT) 5MG · GLP-3 (RT) 10MG (posted COA) · GLP-3 60MG · GLP-3 pen. Orders ship from inside Canada by Canada Post — see the shipping policy for cut-off times, delivery estimates and the free-shipping threshold. Every compound we carry is on the page where you can buy peptides online in Canada.

Frequently asked questions
Can I buy GLP-3 (RT) 20mg in Canada?
Yes. The 20mg vial of retatrutide (sold here as GLP-3 (RT)) is stocked by Shop Peptides Online as research-grade lyophilized peptide and ships from inside Canada by Canada Post. Laboratory research only; the compound is investigational and unapproved.

What does the phase 2 research on retatrutide cover?
Two 2023 trials — one in adults with obesity (PMID 37366315), one in adults with type 2 diabetes (PMID 37385280) — plus substudies on liver fat (PMID 38858523) and body composition by DXA (PMID 40609566). They describe Lilly’s investigational drug under trial conditions; they say nothing about this vial.

Is there a COA for GLP-3 (RT) 20mg?
Not yet. The COA library holds a Janoshik report for a 10 mg vial batch; that document does not cover the 20 mg lot and is not shown here. A 20 mg report will be embedded when one is issued.

Is GLP-3 (RT) 20mg for human use?
No. It is research-grade material for laboratory use only and is not for human or animal consumption. Retatrutide has no marketing approval anywhere; its trials report gastrointestinal adverse events and heart-rate increases (PMID 37366315); and Shop Peptides Online provides no dosing or administration guidance.

References
Coskun T, Urva S et al. (2022). LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. PMID 35985340
Jastreboff AM, Kaplan LM et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial. N Engl J Med. PMID 37366315
Rosenstock J, Frias J et al. (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. PMID 37385280
Coskun T, Wu Q et al. (2025). Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. Lancet Diabetes Endocrinol. PMID 40609566
Sanyal AJ, Kaplan LM et al. (2024). Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. PMID 38858523
Misra S, Narayan RK et al. (2025). Efficacy and safety of retatrutide for the treatment of obesity: a systematic review of clinical trials. J Basic Clin Physiol Pharmacol. PMID 40728138
Simental-Mendía LE, Barragán-Zúñiga LJ et al. (2026). Effect of Retatrutide, a Novel Triple Receptor Agonist, on Blood Pressure and Lipid Levels: A Systematic Review and Meta-analysis of Randomized Controlled Trials. High Blood Press Cardiovasc Prev. PMID 42371360
Laboratory research use only; not for human or animal consumption. This page identifies the material and its literature and claims no efficacy or safety for the product sold.